Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 10.34M | 135.16M | 91.37M | 53.91M | 200.58M | 853.00K |
Gross Profit | 9.43M | 135.16M | -129.20M | 47.16M | 118.29M | -74.03M |
EBITDA | -248.10M | -154.56M | -190.11M | -131.56M | 71.97M | -111.22M |
Net Income | -302.92M | -122.31M | -147.03M | -116.95M | 66.97M | -111.14M |
Balance Sheet | ||||||
Total Assets | 399.07M | 547.11M | 696.38M | 758.03M | 609.37M | 332.98M |
Cash, Cash Equivalents and Short-Term Investments | 371.44M | 471.39M | 618.83M | 710.41M | 579.09M | 295.38M |
Total Debt | 9.78M | 10.84M | 11.84M | 6.47M | 12.33M | 17.84M |
Total Liabilities | 74.73M | 60.18M | 135.02M | 135.99M | 143.32M | 148.97M |
Stockholders Equity | 324.33M | 486.93M | 561.37M | 622.04M | 466.04M | 184.01M |
Cash Flow | ||||||
Free Cash Flow | -196.69M | -150.35M | -136.72M | -109.28M | 92.03M | -80.56M |
Operating Cash Flow | -196.74M | -150.05M | -133.91M | -108.82M | 92.61M | -80.36M |
Investing Cash Flow | -184.94K | -298.00K | -2.77M | -464.00K | -575.00K | -196.00K |
Financing Cash Flow | 147.29K | 1.55M | 45.10M | 241.46M | 190.33M | 215.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $474.20M | -25.43 | -16.87% | ― | 194.98% | 38.01% | |
61 Neutral | $512.39M | -4.23 | -93.19% | ― | 1504.83% | 56.81% | |
58 Neutral | $529.35M | -173.35 | 2.26% | ― | 158.57% | 96.76% | |
46 Neutral | $533.99M | ― | -66.85% | ― | -95.24% | -493.05% | |
43 Neutral | $422.50M | -0.90 | ― | ― | ― | -25.20% | |
41 Neutral | $540.97M | -7.15 | ― | ― | ― | -50.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 27, 2025, Prothena announced results from its Phase 1 ASCENT clinical program for the investigational drug PRX012, aimed at treating early symptomatic Alzheimer’s disease. The study demonstrated that PRX012, a once-monthly, subcutaneous anti-amyloid beta antibody, showed promising results in reducing amyloid plaque but had higher ARIA-E rates compared to FDA-approved antibodies. Prothena plans to seek partnerships to further develop PRX012 and its preclinical PRX012-TfR antibody, which may offer a reduced risk of ARIA and quicker amyloid plaque reduction.
The most recent analyst rating on (PRTA) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
On August 6, 2025, Prothena announced that its partner Novo Nordisk will advance coramitug, a potential first-in-class amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with cardiomyopathy. This decision follows the successful completion of a Phase 2 trial and is expected to commence in 2025. Prothena stands to earn a clinical milestone payment upon meeting specific enrollment criteria in the Phase 3 trial. The advancement of coramitug marks a significant step in addressing the unmet needs of patients with ATTR amyloidosis, potentially enhancing Prothena’s industry positioning and offering substantial financial benefits through its agreement with Novo Nordisk.
The most recent analyst rating on (PRTA) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.